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Resistance-associated mutations in the HIV-1 protease modify viral fitness through changes in the catalytic activity and altered
binding affinity for substrates and inhibitors. In this report, we examine the effects of 31 mutations at 26 amino acid positions in
protease to determine their impact on infectivity and protease inhibitor sensitivity. We found that primary resistance mutations
individually decrease fitness and generally increase sensitivity to protease inhibitors, indicating that reduced virion-associated
protease activity reduces virion infectivity and the reduced level of per virion protease activity is then more easily titrated by a
protease inhibitor. Conversely, mutations at more variable positions (compensatory mutations) confer low-level decreases in
sensitivity to all protease inhibitors with little effect on infectivity. We found significant differences in the observed effect on in-
fectivity with a pseudotype virus assay that requires the protease to cleave the cytoplasmic tail of the amphotropic murine leuke-
mia virus (MuLV) Env protein. Additionally, we were able to mimic the fitness loss associated with resistance mutations by di-
rectly reducing the level of virion-associated protease activity. Virions containing 50% of a D25A mutant protease were 3- to
5-fold more sensitive to protease inhibitors. This level of reduction in protease activity also resulted in a 2-fold increase in sensi-
tivity to nonnucleoside inhibitors of reverse transcriptase and a similar increase in sensitivity to zidovudine (AZT), indicating a
pleiotropic effect associated with reduced protease activity. These results highlight the interplay between enzyme activity, viral
fitness, and inhibitor mechanism and sensitivity in the closed system of the viral replication complex.
The addition of protease (PR) inhibitors (PIs) to antiretroviraltherapies (ARTs) has led to significant reductions in morbidity
and mortality associated with HIV-1 infection (15, 39). Despite
these clinical gains, the benefits of ART can be transitory, with
some individuals experiencing a rebound of viral load (30). Viro-
logic failure of PI-based ART most often occurs because of char-
acteristic mutations in the HIV-1 protease gene (pro) that reduce
the sensitivity of these viruses to one or more inhibitors, and the
presence of drug resistance is a significant barrier to achieving
long-term viral suppression. Although changes at as many as 45 of
the 99 amino acid residues in PR may be associated with selection
by a PI, a subset of approximately 26 positions has been identified
to be those most commonly involved in PI resistance (8, 9, 24, 37,
59). Mutations at the codons encoding these positions typically
accumulate in a stepwise fashion during therapy failure (8, 9, 27,
37, 61), although the order in which they are acquired varies.
PI resistance mutations were originally divided into two
groups: primary or active-site mutations and secondary or com-
pensatory mutations. Primary mutations are often selected early
in the evolution of PI resistance and are required for high-level PI
resistance. These mutations occur at conserved positions that en-
code amino acids that are clustered around the active site of the
enzyme, and these substitutions are generally thought to alter
the Ki of the PI-PR interaction (19, 35, 38, 40, 43, 53). While the
changes in 50% inhibitory concentrations (IC50s) provided by a
single primary mutation are generally small (32, 61), there are
examples where significant resistance can be conferred by a single
amino acid substitution (7, 32, 41). Concomitantly, the altered
enzyme active site is less able to process its normal Gag substrate,
resulting in reduced infectivity of these viruses (10, 13, 48, 60).
Secondary mutations are generally selected later in PI treatment
and occur at codons that encode amino acids outside the enzyme
active site. As single mutations, they do not alter drug sensitivity in
an appreciable manner. The role of secondary mutations in the
evolution of resistance appears to be a compensatory one, as they
encode substitutions that recover fitness losses resulting from the
incorporation of primary mutations (23, 26, 32–34, 42). In some
cases, the amino acid substitutions encoded by secondary muta-
tions have been shown to restore the loss of catalytic activity for
mutant proteases (6, 38, 53), which may explain their mechanism
of compensation.
In the present study, we have analyzed the effects of 31 com-
mon PI resistance-associated mutations on the infectivity of
HIV-1 as a means to evaluate their individual contributions to
viral fitness and their effects on the sensitivity of HIV-1 to each of
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seven approved PIs. These data indicate that the classification of
resistance-associated mutations in pro as primary or compensa-
tory reflects the biological effects of the substitutions encoded at
these positions, as the inclusion of single primary resistance mu-
tations engendered significant fitness losses, while mutations at
the more variable/compensatory positions resulted in smaller fit-
ness changes. There were specific examples where a single primary
resistance mutation conferred net resistance to a specific inhibi-
tor, but in general, there were small increases in sensitivity to PIs
associated with these mutations. Conversely, the compensatory
mutations conferred low-level decreases in sensitivity to all PIs, em-
phasizing the need for multiple mutations to confer high-level resis-
tance to protease inhibitors. When the infectivity values obtained
from the specific infectivity assay were compared to the ones from the
replication capacity assay in which viruses were pseudotyped with the
amphotropic murine leukemia virus (MuLV) Env protein (a modi-
fied version of the PhenoSense assay [12, 44]), we found significant
differences in the effect of the mutations on viral infectivity. Finally,
we were able to mimic the fitness losses associated with primary re-
sistance mutations in the protease by titrating down protease activity
in virions by inclusion of a protease active-site mutant with the wild
type. The reduction in virion-associated protease activity had pleio-
tropic effects on sensitivity to reverse transcriptase (RT) inhibitors
that highlight the distributive nature of both proteolytic processing
and DNA synthesis and the need for multiple enzyme molecules to
carry out these two essential steps in viral replication.
MATERIALS AND METHODS
Plasmids, mutagenesis, and cell culture. The plasmid pARK, containing
the ApaI to RsrII fragment of pNL-CH (described below), was used as a
template for site-directed mutagenesis of the NL4-3 HIV-1 pro gene. Point
mutations were introduced using the QuikChange method (Stratagene)
and were confirmed by sequence analysis. The DNA fragment generated
by digestion with ApaI and RsrII was used to transfer mutated pro se-
quences into the infectious molecular clone pNL-CH, which codes for the
NL4-3 strain of HIV-1 with a silent T-to-C mutation at nucleotide 2600
(relative to the strain HXB2CG sequence) to introduce an RsrII restriction
enzyme site near the 5= end of pol. Two clones of each mutant were iso-
lated, and the nucleotide sequence of the pro gene was confirmed. The 293
cells and the TZM-bl cells (NIH AIDS Research and Reference Reagent
Program) were maintained in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% fetal calf serum in the presence of
penicillin and streptomycin at 37°C with 5% CO2. CEMx174 and H9 cells
were maintained in RPMI 1640 medium supplemented with 10% fetal calf
serum in the presence of penicillin and streptomycin. Cells of the multi-
nuclear activation of a galactosidase indicator (MAGI) cell line were
maintained in DMEM-high glucose (DMEM-H) medium, which con-
sisted of DMEM supplemented with 10% fetal bovine serum, 0.1 mg/ml
G418, and 0.1 mg/ml hygromycin B. The TZM-bl cells are HeLa cells
which stably express CD4 and CCR5 (57).
Virus stocks. One day prior to transfection, 3  105 293 cells were
plated in each well of a 24-well plate. Transfections of 0.5 g of plasmid
DNA were done with each mutant plasmid using Fugene transfection
reagent (Roche) according to the manufacturer’s instructions. For the
phenotypic mixing experiments, a version of pNL-CH with a mutation at
the codon encoding the active site of the protease (D25A) was cotrans-
fected with wild-type (WT) DNA at various ratios of the two plasmids
while maintaining the total DNA at a fixed mass. After 48 h, virus-
containing culture supernatants were collected, filtered through a 0.45-
m-pore-size membrane (Millipore) to remove cell debris, and stored at
80°C.
Real-time RT-PCR. Cell-free virions harvested from transfected 293
cells were treated with RNase-free DNase (Promega) at 37°C for 1 h to
remove any residual plasmid DNA carried over from the transfection.
Sindbis virus (Girdwood strain; a gift from Mark Heise) was also treated
with RNase-free DNase and used as an internal control for real-time PCR.
Viral RNA was extracted using a QIAamp viral RNA kit (Qiagen). The
amount of encapsidated genomic viral RNA was detected by quantitative
real-time RT-PCR using a TaqMan one-step RT-PCR master mix reagent
kit (Applied Biosystems) and an ABI 7000 sequencer detector (Applied
Biosystems) and normalized by the amount of Sindbis viral RNA. The
sequences of the primers and probe to detect the HIV-1 gag region were
previously described (16). Sindbis virus RNA was detected using primers
SINRT-F (5=-GCCGCACACGACAATTCAC-3=) plus SINRT-R (5=-GTA
CCCTCGTACACGGACGAA-3=) and a probe, SINRT-P (5=-FAM-CCG
CATCATCTGAATTG-MGBNFQ-3=, where FAM is 6-carboxyfluores-
cein), which detect the NSP2 region of the genome.
Quantitative determination of CA protein. The amount of capsid
(CA) protein (p24) in the transfection supernatants was measured by an
enzyme-linked immunosorbent assay (ELISA) using a set of reagents
available from the National Cancer Institute AIDS Vaccine Program by
following the manufacturer’s instructions. Lysed samples were further
diluted at least 50-fold prior to sample binding. All samples were mea-
sured in duplicate at two dilutions. Masses were calculated from the stan-
dard curve using the average optical density of the duplicate measure-
ments. The dilution-corrected masses were then averaged to determine
the final mass of p24 in each transfection supernatant.
Specific infectivity (SpIn) assay. Virus stocks (i.e., the transfection
supernatants) were used to infect TZM-bl cells (14, 57), seeded at 1.3 
104 cells per well of a 96-well plate 24 h prior to infection. Two dilutions of
the transfection supernatant from each mutant, as well as the wild-type
NL4-3 transfected in parallel, were used to infect TZM-bl cells in dupli-
cate. After 48 h of incubation, the cells were washed with 150 l of Dul-
becco’s phosphate-buffered saline (PBS), lysed in 50 l of reporter lysis
buffer (Promega), and stored at 80°C. After one freeze-thaw cycle, 30 l
of cell lysates was transferred into a 96-well assay plate (Costar) and lucif-
erase (Luc) activity was measured using a luminometer (Promega). Any
infections for which the values of the corrected relative light units (RLU)
of the two dilutions differed by greater than 30% were discarded. The
values of the specific infectivity were normalized either by the amount of
p24 determined from the ELISA or by the level of viral RNA determined
from the real-time RT-PCR and compared to the value for the parental
strain, which was given a value of 1.
RC assay. Mutant pro sequences were cloned into a previously de-
scribed replication-incompetent HIV-1 vector that contains a luciferase
gene inserted into a deleted portion of the env gene (44). The replication
capacity (RC) assay is a modified version of the PhenoSense assay origi-
nally designed to measure HIV-1 drug susceptibility (12, 44). Briefly, virus
stocks were produced by cotransfecting 293 cells with the HIV-1 luciferase
vector encoding the pro sequence of interest and an MuLV amphotropic
env-expressing DNA construct. Virus particles were harvested at 48 h after
transfection and were used to infect target 293 cells for 48 h. The ratio of
luciferase activity in the infected cells to luciferase activity in the trans-
fected cells was calculated to give the single-cycle RC value relative to the
wild-type virus, which was given an RC value of 1 (12).
Growth competition assay. Virus stocks of M46I, G48V, L63P, V82A,
I84V, L90M, and wild type (NL-CH) were used to infect 3  106
CEMx174 cells in 500 l. A total of 3  103 infectious units of virus,
determined using cells of the MAGI cell line, was mixed with the cells (29).
Ratios of input infectious units for the two viruses (WT and mutant) in
coculture were 1:1 in all cases except for WT/L63P and WT/G48V, where
the input ratios were 1:2 and 1:200, respectively. For infection, cells were
incubated at 37°C for 2 h, the unbound virus was removed by washing
twice with PBS, and the cells were resuspended in a 10 ml of RPMI 1640
medium. The cells were washed to minimize the measurement of input
virus in the medium. On each day that the cells were centrifuged, super-
natants were collected and fresh medium was added to the culture until
the beginning of syncytium formation was detected. Collection was
Henderson et al.
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stopped when the first syncytia appeared to ensure that cells were in excess
over the virus during the period of analysis.
To quantitate relative viral growth, the culture supernatants (har-
vested each day, usually days 1 to 3) were treated with RNase-free DNase
(Promega) at 37°C for 1 h, viral RNA was extracted using a QIAamp viral
RNA kit (Qiagen), and real-time RT-PCR was performed using a TaqMan
one-step RT-PCR master mix reagent kit (Applied Biosystems) to docu-
ment an increase in virus over input. Sindbis virus was used as an internal
control to normalize the recovery of viral RNA during the extraction step.
To assess the ratio of the wild-type and mutant viruses in the culture
supernatant, a heteroduplex tracking assay (HTA) analysis was performed as
described by Resch et al. (47). Briefly, the plasmid pPR-EB was used to gen-
erate a labeled probe spanning most of the pro gene. A 247-bp fragment of pro
was amplified from viral RNA using primers PRAMPUP (5=-AACTAAAGG
AAGCTCTATTAGATACAGGAG-3=) and PRAMPDW (5=-GGAAAATT
TAAAGTGCAACCAATCTGA-3=). The labeled probe was annealed to
the PCR products representing each day of culture growth, and the labeled
heteroduplexes were resolved in a native polyacrylamide gel. The relative
abundance of the wild-type and mutant sequences was determined from
the intensities of their relative heteroduplexes in the gel, and the magni-
tude of change in this ratio per day was used to calculate the relative fitness
of the mutant compared to the wild type (47).
Silver staining. A 1-ml aliquot of transfection supernatant was centri-
fuged at 21,000  g for 1.5 h in a microultracentrifuge. The pelleted virus
particles were lysed in 25 l of sample lysis buffer (50 mM Tris-HCl, 0.1 M
NaCl, 1 mM EDTA, 50 l of Nonidet P-40, and 1 protease inhibitor tablet
[Roche] in 25 ml). Volumes containing equivalent masses of p24, as
measured by ELISA, were subjected to denaturing Tricine-SDS-
polyacrylamide gel electrophoresis as described previously (52) in a 12%
acrylamide gel. Proteins were visualized by silver staining according to the
manufacturer’s instructions (Bio-Rad).
Western blot analyses. Viruses pseudotyped with MuLV amphotro-
pic Env protein were harvested from the 293 cells at 48 h after transfection,
filtered through a 0.45-m-pore-size membrane (Millipore) to remove
cell debris, and concentrated by ultracentrifugation at 24,000 rpm for 2 h
at 4°C using an SW 41 Ti rotor (Beckman). The pelleted virus particles
were analyzed to examine viral proteins using polyclonal rabbit anti-
MuLV p15E antibody (a kind gift from Alan Rein, NCI-Frederick) or
polyclonal rabbit anti-HIV-1 p24 antibody (NIH AIDS Research and Ref-
erence Reagent Program). To detect HIV-1 reverse transcriptase (p66/
p51), polyclonal rabbit anti-HIV-1 RT antibody (NIH AIDS Research and
Reference Reagent Program) was used.
Resistance testing. Sensitivity to inhibitors was measured using the
PhenoSense assay (44). Briefly, virus stocks were prepared as described for
the RC assay, but with the addition of serially diluted PI to the cultures at
approximately 16 h posttransfection. The addition of RT inhibitors was
done at the time of infection. Virus stocks were collected at 48 h posttrans-
fection and used to infect new 293 cell cultures to determine the percent
reduction in infectivity, as measured by residual luciferase activity. Inhi-
bition curves were constructed by fitting these data to a sigmoidal func-
tion from which the drug concentration at which 50% of viral infectivity
was inhibited (50% effective concentration [EC50]) could be calculated.
The fold change (FC) in EC50 (FC EC50) value was determined by com-
paring the EC50 for the protease mutant virus to the EC50 for a wild-type
virus. The FC EC50 values obtained from 7 different protease inhibitors
(amprenavir [APV], atazanavir [ATV], indinavir [IDV], lopinavir [LPV],
nelfinavir [NFV], ritonavir [RTV], and saquinavir [SQV]) were used to
calculate the mean FC EC50 values and standard deviations of each mutant
for all inhibitors combined.
RESULTS
Specific infectivity (SpIn) measurements of viruses with single
mutations associated with protease inhibitor resistance. Using a
single-cycle SpIn assay, we have measured the effects of point mu-
tations in pro on the average per particle infectivity of HIV-1. To
conduct the SpIn assay, the relative number of infectious units
present in a transfection supernatant was measured using TZM-bl
cells, which express Luc upon productive infection by HIV-1.
These values were then divided by the mass of p24 CA protein
in the transfection supernatant, measured by an antigen-
capture ELISA, to give a ratio of the relative number of infec-
tious units per unit mass of p24. Finally, the Luc/p24 ratio for
each mutant virus was divided by the Luc/p24 ratio for the
parental wild-type virus, which was measured in parallel.
While the in vivo fitness of a virus is impacted by many factors
(including the presence of an inhibitor), SpIn specifically re-
flects the changes in the ability of a virus to complete the infec-
tion cycle from target cell entry through viral gene expression.
Therefore, mutations that result in a reduction in virus release
would not score in this assay.
We were concerned that CA in unprocessed or partially pro-
cessed Gag polyproteins might not be detected with the same sen-
sitivity as the mature, fully processed p24. To assess whether such
a bias exists in our data set, we used silver staining to examine
SDS-polyacrylamide gels run with virus lysates containing equiv-
alent masses of p24 measured by ELISA (Fig. 1A). Serial dilutions
of lysates from the parental NL4-3 virus and a G48V mutant,
which is poorly infectious (see below), were compared. Approxi-
mately equivalent staining intensity was detected for the bands
corresponding to CA and CA-SP1 (p24 and p25) and to MA
(matrix, p17) of the wild type (lanes 1 to 3) and the mutant (lanes
FIG 1 (A) Silver staining showing that p24 ELISA measures equal amounts of
Gag products from the wild-type and protease mutant virion. An SDS-
polyacrylamide gel was loaded with equal masses of p24, as determined by
antigen-capture ELISA. The band signals were compared for the parental
NL4-3 virus (lanes 1 to 3) and the poorly infectious G48V mutant (lanes 4 to
6). Threefold dilutions of each mutant were shown (lanes 1 and 4, 150 ng of
p24; lanes 2 and 5, 50 ng of p24; lanes 3 and 6, 17 ng of p24). (B) Correlation
analysis between SpIn values measured using the p24 ELISA and SpIn values
measured using real-time RT PCR. The r2 value was obtained from the statis-
tical analysis using nonparametric (Spearman) correlation.
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4 to 6), indicating that the estimates of protein mass were not
seriously discrepant. However, because of concerns about the
ability of the ELISA to measure processing intermediates that
may constitute small amounts of the total virion protein, we
also used a real-time RT-PCR assay to measure the amount of
viral RNA in virus particles. When we compared the SpIn val-
ues obtained from two different normalization methods, using
either p24 or virion RNA, as can be seen in Fig. 1B, there was a
good correlation (r2  0.55 and P  0.0001) between these
values, with no systematic differences among different classes
of protease mutations. This result again confirms that the SpIn
value determined by normalization to the value for p24 mea-
sured by ELISA did not introduce a systematic error compared
to normalization to the value for virion RNA.
The SpIn values normalized by either p24 values or viral RNA
values for 31 mutant viruses containing a single mutation in pro-
tease are shown in Fig. 2A. Mutations were classified on the basis
of their amino acid sequence variability in viral pro sequences
obtained from PI-treated and untreated subjects (24). Class 1 mu-
tations are found at a similar frequency in both PI-treated and
untreated subjects (I15V, E35D, N37D, I64V), class 2/secondary
or compensatory mutations are found in untreated subjects, but
their frequency increases in treated subjects (L10I, M36I, I62V,
L63P, A71V/T, V77I, I93L), and class 3/primary resistance muta-
tions appear only in treated subjects (K20I/R, D30N, V32I,
M46I/L, G48V, I54V, G73S, V82A/T, I84V, N88D/S, L90M). We
have included the mutations L24I, I47V, I50V, and F53L in the
class 3/primary group because they are selected by PIs (for a re-
view, see reference 22) and are not found in the absence of PI
selection (24).
The effects of mutations at class 1 positions on viral fitness
are fairly small compared to the wild-type value. These are the
most variable positions in the protease whose variability is not
affected by the evolution of resistance, suggesting that substi-
tutions at these positions are likely to have little to no effect on
viral replication, consistent with the observation that the SpIn
values for these mutants remain close to 1 (Fig. 2A). Similar
results were obtained from the class 2/secondary mutations,
having the SpIn values close to the level of wild type (Fig. 2A).
The only exception was the M36I mutant, which was reduced
about 2-fold compared to the wild type. As predicted by their
absence without selection by a PI, most mutations at class
3/primary resistance positions in PR resulted in a loss in infec-
tivity. Many of the SpIn values for class 3 mutations were well
below 0.8, with the lowest value of 0.12 measured for the I50V
mutant. In addition to the I50V mutant, D30N, G48V, F53L,
and I54V also showed impaired infectivity with values of
about 0.5.
Replication capacity values of viruses with single mutations
associated with protease inhibitor resistance. As a complemen-
tary comparison to the SpIn assay, we have also used the RC assay
(5, 12, 44), which is a related but alternative single-cycle method
for examining the fitness effects of mutations in pro. While the
SpIn assay measures the effects of mutations on the early steps of
infection for infectious HIV-1, the RC assay measures the infec-
tivity of HIV-1 pseudotyped with the MuLV amphotropic Env
FIG 2 Infectivities of HIV-1 bearing single resistance-associated mutations in pro measured by two separate single-cycle assays. (A) SpIn assay, in which the
amount of viruses used for infection was normalized by measuring either p24 mass (ELISA) or viral RNA (real-time RT-PCR). All the values are normalized to
that for the parental NL4-3 strain, which is given an infectivity of 1.0. Data from either two or more than two infection values were averaged, and the infectivity
data are shown as means  standard deviations. Standard deviation values for L10I, K20R, and I50V are not determined. (B) RC assay in which the viruses were
pseudotyped with the MuLV amphotropic Env protein. Since a luciferase expression cassette is inserted within a deleted region of the HIV-1 env gene, the ratio
of luciferase activity in the infected cells to that in the transfected cells was used to normalize viral infectivity. The variability of the RC assay has been validated
to be 0.2 log.
Henderson et al.
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protein relative to the luciferase expression in the transfected cells that
produce virus, thereby incorporating any potential effects of these
mutations on virus production into the final RC value. In addition,
RC records any effects of mutations in PR on the processing of the
C-terminal tail of the MuLV amphotropic Env protein, a step re-
quired for activation of the fusion capacity of the MuLV Env protein
(46). We have previously observed for a small number of mutants
that RC values can cover a wider range of values than those reported
by the SpIn assay (48). The RC values for the full set of mutants
described in the SpIn assay are shown in Fig. 2B.
Viruses with class 1 mutations had a wider range of RC values
than the corresponding SpIn values, especially for E35D (with a
2-fold decrease). For most of the class 2/secondary mutations, the
RC values were either higher than (L10I, M36I, I62V, L63P, V77I)
or identical to (A71V, A71T) the SpIn values, with only one ex-
ception, where the RC was lower (I93L). Several of the class 2/sec-
ondary mutations had RC values greater than 1, suggesting en-
hanced infectivity in this assay.
More dramatic differences between RC and SpIn assay values
were seen in comparing the class 3/primary resistance mutations
(Fig. 2A and B), such that an overall comparison of RC and SpIn
values for all mutants showed no correlation (P  0.45; data not
shown). Only 3 of the 19 mutants in this class had similar RC and
SpIn values (the flap mutants M46I, F53L, and I54V, with a dif-
ference between RC and SpIn assay values of less than 0.2), and 1
had a higher RC value (I47V). In all other cases, the RC value was
much lower than the SpIn value, indicating that the two assays
have very different readouts for the effects of these mutations on
infectivity. The mean value for the mutants with class 3 mutations
tested in the SpIn assay was 0.7 but was only 0.3 in the RC assay.
In an effort to determine which of these assays more accurately
reflects the fitness effects of these protease mutations, we also ex-
amined a subset of mutants using a growth competition assay. In
this analysis, the wild-type virus and the mutant virus are cocul-
tured and the relative ratio of the two viruses is measured daily as
they expand through the culture. To determine the relative fitness,
the change in abundance of the mutant relative to the wild type is
calculated per day, which is assumed to be the generation time of
the virus. When we compared the fitness values determined by the
growth competition assay for mutants L63P, M46I, G48V, V82A,
I84V, and L90M, we found that the values obtained were more
similar to those of the SpIn assay than the RC assay, with values in
good agreement with earlier studies (Table 1) (23, 32–34, 50).
Unprocessed p15E MuLV TM protein contributes to the
lower RC values for pseudotyped viruses with class 3 mutations.
In the RC assay, the viruses are pseudotyped with the MuLV am-
photropic Env protein, which requires proteolytic cleavage of the
transmembrane (TM) protein (p15E) by the virally encoded pro-
tease for its fusogenic activation (46). This proteolytic processing
generates a mature TM protein (p12E) and a 16-amino-acid R
peptide (18, 20). Therefore, it is possible that the effects of the
impaired catalytic activity of a mutant HIV-1 protease might be
amplified by the requirement for cleavage of the amphotropic Env
TM subunit. To test this possibility, we selected 11 mutants based
on RC values ranging from wild-type to background levels and
pseudotyped the virions by adding an expression vector for the
MuLV amphotropic env gene used in the RC assay. Phenotypically
mixed virions, containing both the HIV-1 Env protein and the
MuLV amphotropic Env protein, were analyzed to examine
whether the impaired RC values were associated with unprocessed
p15E TM protein in virions. As seen in Fig. 3, the mutants with
high RC values (L63P and I47V) showed complete processing of
p15E protein; however, the amount of the unprocessed p15E pro-
tein in the virion was gradually increased with decreasing RC value
(Fig. 3). The p12E protein was not detected for the mutants N88S
and N88D, which had RC values close to background. Since the
amount of processed CA protein detected from each mutant was
not greatly affected by the mutations in the class 3 positions, it is
likely that the impaired RC values are the result of the lack of
processing of the p15E protein in the virion. The only exception
among the mutant viruses that we tested was the G48V mutant,
which showed more processed p12E protein than unprocessed
p15E protein, although the RC value was only 0.04, presumably a
reflection of intermediate Env processing plus a reduced fitness
value (Fig. 2A).
Effect of single resistance-associated mutations in HIV-1 PR
on PI sensitivity. The PI sensitivities of viruses bearing each of the
mutations described above were measured using the PhenoSense
assay (44). In this strategy, we took advantage of the increased
sensitivity of the pseudotyped virus to measure small changes in
drug sensitivity due to limiting amounts of protease activity. The
FC EC50, which is the amount of PI required to inhibit 50% of the
infectivity of a mutant virus relative to the amount of drug re-
quired to inhibit 50% of the wild-type virus infectivity, was mea-
sured for each of seven approved PIs (APV, ATV, IDV, LPV, NFV,
RTV, and SQV; Fig. 4; see Table S1 in the supplemental material).
In this analysis, we have defined a specific interaction between the
FIG 3 Western blot analysis of the selected protease mutant virus particles
pseudotyped with the MuLV amphotropic Env protein. Each infectious HIV-1
clone containing the indicated single resistance-associated mutation in the pro
region was used along with the MuLV amphotropic Env plasmids to transfect
293 cells. Culture supernatants were harvested at 48 h after transfection and
were subjected to ultracentrifugation to concentrate the viral particles. The
pelleted viral particles were detected using either anti-MuLV p15E antibody or
anti-HIV-1 CA antibody as the primary antibody. For comparison, MuLV
particles and HIV-1 protease active-site mutant (D25A) are shown. Unpro-
cessed p15E protein was not detected from the MuLV particles, and in con-
trast, only unprocessed p15E protein was detected from the D25A mutant.
TABLE 1 Relative fitness values of viruses containing a PI resistance-





M46I/WT 1.00  0.03
G48V/WT 0.53  NDa
L63P/WT 1.02  0.12
V82A/WT 0.85  0.06
I84V/WT 0.78  0.04
L90M/WT 0.98  0.04
a ND, not determined.
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inhibitor and the mutant protease as having an FC EC50 greater
than 2 standard deviations above the mean of all seven FC EC50
values (indicated by open circles in Fig. 4). We pooled the values
that did not reach the definition of specific interaction to assess the
overall effect of these mutations on the EC50.
As was observed for their impact on infectivity, the effects of
these mutations on FC EC50 can be generalized by mutation class.
The incorporation of either a class 1 or class 2 mutation in pro did
not cause a large shift in EC50 (Fig. 4). Furthermore, the FC EC50
responses for these mutants did not vary significantly by drug, as
indicated by the small standard deviations of these pooled mea-
surements. Most often, the FC EC50 values for these mutants mir-
rored their RC values, with mutants that had RC values near 1
showing little change in EC50, while those that had reduced infec-
tivity, such as E35D and I93L, were more sensitive to the PIs. The
FC EC50 values for I15V and A71V/T break this trend, as they had
higher EC50 values than would have been predicted on the basis of
their RC values. Also, the class 2/secondary mutations L10I, L63P,
and A71V/T showed a small but largely consistent decrease in
drug sensitivity across the protease inhibitors, suggesting that the
effects of these mutations were on the protease and not on the
interaction between protease and inhibitor.
Most viruses (14 out of 19) bearing mutations at class 3/pri-
mary resistance positions exhibited a decrease in FC EC50 (in-
creased PI sensitivity), as shown in Fig. 4 and 5. This suggests that
for many mutation/PI combinations there was a sensitization of
the protease to inhibition by a PI that outweighed the effect on
resistance. There were exceptions to this general trend, with in-
creases in FC EC50 (PI resistance) occurring for expected specific
pairings of mutant and PI and with high levels of PI resistance
being observed for D30N (which provided a 6-fold increase in
EC50 for NFV) and G48V (which provided a 9-fold increase in
EC50 for SQV); in addition, G48V conferred decreased sensitivity
to all inhibitors, in spite of being one of the less fit proteases.
Mutations K20I and V82A/T also conferred significantly higher PI
resistance to one PI of the panel (K20I with NFV and V82A/T with
RTV). The FC EC50 responses for V32I and I50V with APV ap-
proached this cutoff. In contrast, the observed increase in suscep-
tibility for a large number of mutants with class 3 mutations ap-
proached or exceeded 2.5-fold (FC EC50, 0.4 or less). At the
extreme, the N88S mutant displayed a specific hypersensitive re-
sponse to APV (open circle in Fig. 4), as reported previously (62).
The lower mean values of FC EC50 for the viruses with class 3
mutations compared to the viruses with class 2 mutations are
shown in Fig. 5. We interpret the general increase in sensitivity to
reflect the fitness loss associated with these mutations. However,
the outliers conferring either reduced sensitivity (e.g., D30N,
G48V, and V82A/T) or dramatically increased sensitivity (e.g.,
N88S) reflect direct changes in the interaction between the pro-
tease and the inhibitor that confer net resistance (or sensitivity), in
spite of the fitness loss. In the absence of a strong specific interac-
tion with the PI, the increase in sensitivity reflects the net loss in
catalytic capacity within the virus particle due to the presence of
the resistance mutation and the more limited requirement of the
PI to titrate down the residual protease activity.
Effect of reduction in protease activity on virion infectivity
and inhibitor sensitivity. We have interpreted the general neg-
ative effect of the class 3/primary resistance mutations on vi-
rion infectivity as being due to a decrease in total virion-
associated protease activity. We modeled this effect by directly
reducing the amount of protease activity in the virion. We
accomplished this by mixing the infectious molecular clone
with an isogenic clone containing an inactivating mutation at
FIG 4 FC EC50s of mutants to protease inhibitors. The EC50 was measured for each mutant virus with each of the seven approved protease inhibitors (APV, ATV,
IDV, LPV, NFV, RTV, and SQV) and compared to the EC50 of the parental virus to calculate the FC EC50. Values are presented on a log scale as the average FC
EC50 (filled circles), with error bars indicating the standard deviation of these values. Those FC EC50 values which are greater than 2 standard deviations from the
mean of all seven FC EC50s are indicated by open circles (K20I, NFV; D30N, NFV; G48V, SQV; V82A, RTV; V82T, RTV; and N88S, APV), and they are excluded
from the calculation of the average FC EC50 and standard deviation.
FIG 5 Comparison of average FC EC50 between class 2 and class 3 mutations.
The solid horizontal lines represent the median FC EC50 in each group. The
mean FC EC50 values between class 2 and class 3 mutations were compared by
statistical analysis using a Mann-Whitney test (nonparametric). The outliers
shown as open circles in Fig. 4 are not included in the analysis.
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the codon encoding the protease active site, D25A. By titrating
in an increasing proportion of the protease mutant, we were
able to decrease protease activity nonspecifically. Since the pro-
tease functions as a homodimer, the fraction of protease dimers
that are active is the square of the fraction of the infectious
genome compared to the total viral DNA.
The amount of mutant DNA was varied relative to the amount
of wild-type DNA, and the infectivity was recorded by both the
SpIn assay and the RC assay. As can be seen in Fig. 6A, the two
assays had different responses to the inclusion of the mutant DNA.
The RC assay showed a linear decrease with increasing amounts of
the D25A mutant. In contrast, increasing the amount of the D25A
mutant in the SpIn assay resulted in a biphasic reduction in virion
infectivity. As shown in Fig. 6D, processing intermediates were
apparent in the virion in the presence of 50% of the D25A mutant
protease subunits, representing 25% residual protease activity.
We next tested the possibility that the amount of protease ac-
tivity could affect sensitivity to inhibitors of viral replication by
comparing the EC50 for the D25A-containing viruses to the EC50
for the wild-type viruses. As can be seen in Fig. 6B and Table S2 in
the supplemental material, increasing the amount of mutant pro-
tease up to 50% (equivalent to 25% residual protease activity, the
greatest reduction in protease level that could be attained while
allowing some residual infectivity in the PhenoSense assay) had a
systematic effect on the EC50 value for the three classes of antiviral
drugs tested. In the presence of 50% mutant (D25A) protease, the
nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)
abacavir (ABC), didanosine (ddI), emtricitabine (FTC), lamivu-
dine (3TC), stavudine (d4T), and tenofovir (TFV) showed only a
small effect, with an approximately 20% to 30% decreases in the
EC50s. The exceptions to this trend were zalcitabine (ddc), for
which there was no change in the EC50, and zidovudine (AZT), for
which there was a decrease of nearly 2-fold. The magnitude of
change in EC50 for AZT was similar to that seen with the four
nonnucleoside RT inhibitors (NNRTIs) delavirdine (DLV), efa-
virenz (EFV), entecavir (ETV), and nevirapine (NVP), which,
again, was in the range of a 2-fold change in the EC50 in the pres-
ence of 50% mutant (D25A) protease. An even larger effect was
seen among the nine protease inhibitors tested, with decreases in
the EC50 ranging from 2.4-fold to 5.3-fold.
These experiments show that by simply decreasing the total
amount of protease activity in the virion, we could alter the sen-
sitivity to all three of these classes of inhibitors, with the magni-
tude of the effect being associated with the inhibitor class and with
the protease inhibitors showing the largest effect (Fig. 6C). The
pleiotropic effect seen with RT inhibitors is likely the result of the
reduced protease activity resulting in a reduced amount of pro-
cessed RT (Fig. 6D), thus also reducing the amount of total RT
activity present in the virion.
DISCUSSION
Previous studies have demonstrated that losses of infectivity are a
consequence of resistance-associated mutations in the HIV-1 pro-
tease; however, the contributions of individual mutations to
FIG 6 Effect of nonspecific loss of protease activity on viral infectivity and inhibitor sensitivity. (A) Protease activity was reduced in a nonspecific way by
transfecting the infectious molecular clone with an isogenic clone containing an inactivating mutation at the protease active site (D25A). Both the fraction of the
D25A mutant and the calculated remaining protease activity in each preparation are indicated. The relative infectivity of each mixture was measured using the
SpIn (filled circles) and RC (open circles) assays. (B) The effect of nonspecific loss of protease activity on sensitivity to inhibitors of HIV replication was studied by
measuring the EC50 for nucleoside reverse transcriptase inhibitors (tenofovir, AZT), nonnucleoside reverse transcriptase inhibitors (EFV), and protease inhibitors (LPV,
darunavir [DRV]). Increasing the amount of mutant protease up to 50% (equivalent to 25% residual protease activity) had a systematic effect on the EC50 value for the
three classes of antiviral drugs tested. (C) The FC EC50 of 50% D25A relative to the FC EC50 of 0% D25A is shown for all the inhibitors tested. The values of three classes
of inhibitors were compared by statistical analysis using a nonparametric Kruskal-Wallis test. The open arrowhead indicates the value from AZT. (D) Western blot
analysis showing the extent of processing of p24 and RT in virus particle preparations containing either 100% WT or 50% inactive mutant protease.
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changes in fitness have previously been measured for only a subset
of these mutations. Therefore, in an effort to acquire a systematic
comparison of the effect of HIV-1 PI resistance mutations on viral
fitness, in this study the relative fitness and protease inhibitor
sensitivity of 31 viruses each bearing a single resistance-associated
mutation in the HIV-1 protease were characterized using two dif-
ferent assays, the single-cycle SpIn assay and the RC assay. We
found a profound discrepancy in the fitness results between two
assays, especially for the mutants with mutations in the class 3
group, where the protease sequence is largely conserved in the
absence of a protease inhibitor but becomes variable after selec-
tion by a protease inhibitor. Our results demonstrate that the SpIn
assay results correlate better with the results of the growth com-
petition assay than the RC assay results do for viruses bearing
single PI resistance mutations (Fig. 2 and Table 1). However, in
understanding the differences between these assays, we gained
insight into the interaction between protease activity, virion
infectivity, and inhibitor resistance that highlights the need for
multiple enzyme molecules to carry out efficiently the steps of
proteolytic processing and DNA synthesis.
The single-cycle SpIn assay is similar to assays described previ-
ously (3, 34, 48, 60), in which the infectivity of each virus prepa-
ration was measured using a reporter cell line and normalized by
the amount of virus used for infection. We used several ap-
proaches to show that underprocessing associated with reduced
protease activity did not significantly influence our estimation of
virion mass in normalizing the different virus preparations. As
expected, the fitness values measured by the SpIn assay showed a
general trend in the three classes of mutations defining variability
in the protease (Fig. 2A). Class 1 mutations, which have similar
variability in the sequence database regardless of exposure to pro-
tease inhibitor, and class 2 mutations, which are seen in the
absence of exposure to protease inhibitors but have increased vari-
ability when exposed to these inhibitors, had values close to wild-
type level (except for M36I), consistent with these mutations be-
ing tolerated within the broad viral population. In contrast,
obvious effects on the viral infectivity were seen more frequently
with the resistance-associated class 3 mutations, particularly with
the flap mutations, G48V, I50V, F53L, and I54V, giving viruses
with infectivity values of less than 0.6. Overall, these results are
consistent with the fitness values of several mutants reported in
the previous studies (32, 50) and collectively provide a much more
complete view of the effect of these 31 protease mutations on
infectivity. Several studies have reported an increase in fitness as-
sociated with some class 3 mutations (32, 50). This can be a feature
of a transfection-based approach to generating virus, in that pro-
tease may be overproduced in the transfected cells, such that a
small reduction in protease activity with either a slightly attenuat-
ing mutation, a small amount of a protease inhibitor (data not
shown), or a small amount of phenotypic mixing with a mutant
with an active-site mutation (Fig. 6A) can give an apparent in-
crease in virion infectivity. We interpret these results as indicating
that the SpIn assay slightly overestimates the fitness value in the
range of 0.1 or less.
There were differences in the fitness values when the values of
the SpIn assay and the RC assay were compared (Fig. 2B). In gen-
eral, the RC values of the mutants with class 2 mutations were
higher than the SpIn values, with mean values of 1.1 and 0.8,
respectively, and the RC values of the mutants with class 3 muta-
tions were typically lower than the SpIn values, with mean values
of 0.3 and 0.7, respectively. In the RC assay, the viruses are pseu-
dotyped with the MuLV amphotropic Env protein. The cytoplas-
mic tail of the MuLV TM protein must be cleaved to induce a
fusogenic state in the Env protein, a step necessary for MuLV
infection. It has been reported that this site is efficiently cleaved by
the HIV-1 protease (28), although the cleavage site (VQAL/
VLTQ) is suboptimal for HIV-1 protease, with small aliphatic
amino acids at P1 and P1=. If cleavage of this heterologous site is
actually limiting for infection, then we would predict increases
and decreases in infectivity based on both nonspecific changes in
protease activity and specific changes in the interaction with the
heterologous cleavage site. Consistent with this interpretation,
our Western blot analysis demonstrated a strong correlation be-
tween the RC values and the level of the processed MuLV TM
protein (p15E) in the virion (Fig. 3). The viruses with low RC
values contained more unprocessed p15E protein than processed
p12E protein and vice versa, suggesting that the infectivity value
recorded from the RC assay includes a component that depends
on the extent of processing of the MuLV TM protein. Thus, the
increase in RC values associated with mutants with class 2 muta-
tions can be viewed as a nonspecific increase in protease activity.
Conversely, the low values of the mutants with class 3 mutations
represent the reduced activity seen in the SpIn assay. The very low
RC values recorded for some mutants likely reflect steric clashes
between the protease mutant side chain and the MuLV Env cleav-
age site, even though some of these mutations (e.g., G73S and
N88D) make the PR more MuLV-like (45), indicating the intri-
cate nature of substrate recognition. Conversely, several muta-
tions in the flap, such as M46I and I47V, may enhance the cleavage
of this heterologous site. Similarly, the G48V flap mutant gener-
ated relatively high levels of processed p12E protein but still had a
low RC value, suggesting that the low RC value was the sum of
moderate levels of p15E processing and the reduced infectivity
associated with this mutation seen in the SpIn assay. Thus, the RC
assay represents a complex sum of protease interactions with the
heterologous p15E cleavage site and the processing cascade
needed for the generation of an infectious HIV-1 core. This sug-
gests that the use of RC data to infer features of viral sequence
interactions within the protease on a population level (21) is prob-
lematic.
Although the RC assay appears to be limited in its ability to
measure absolute fitness changes, the presence of the MuLV cleav-
age site as a limiting event in virion infectivity can be useful for
measuring small changes in protease activity (Fig. 4). When the PI
sensitivity of the 31 viruses to 7 different PIs was measured by the
PhenoSense assay, mutations at class 1 positions did not provide
any PI resistance, as predicted by their lack of positive selection by
PI. Likewise, mutations at class 2 positions led to only small
changes in EC50s, in agreement with the previous studies (9, 10,
32, 33, 38, 42), with some of the mutants showing a small but
consistent decrease in sensitivity across the different inhibitors.
This is consistent with the idea that mutants with these mutations
have increased protease activity and can partially overcome the
effect of the protease inhibitor titrating out protease activity in the
virion. In contrast, most of the mutants with class 3 mutations
showed increased sensitivity to most of the protease inhibitors,
which is consistent with the idea that the reduced activity of these
protease mutants makes it easier to titrate out the remaining pro-
tease activity by the protease inhibitor to effect a loss of virion
infectivity (Fig. 5). The exceptions were the specific/high-level
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protease inhibitor resistance provided by mutants with class 3
mutations with certain protease inhibitors, in agreement with
those reported previously (9, 32, 33). However, it is now clear that
the reduced sensitivity to specific PIs is in the background of re-
duced protease activity that increases sensitivity to PIs in general
(Fig. 4). In many cases, the increase in PI susceptibility ap-
proached the 2.5-fold (FC EC50  0.4) cutoff which has been used
to define hypersensitivity (HS) in previous studies (see Table S1 in
the supplemental material) (31, 48, 58). The hydrophobic substi-
tutions in flap positions 46, 47, and 48 appear to provide a general
resistance to protease inhibitors (albeit at a low level), perhaps by
a mechanism that is similar to their ability to enhance interaction
with the heterologous p15E substrate (as discussed above). While
the analysis of single class 3 mutations reveals their individual
impact on protease activity, this approach does not include the
contribution that some of these mutations can make in the con-
text of multiple mutations (49) and in the background of class 2
mutations that can compensate for the reduced protease activity
to confer high-level resistance to protease inhibitors (34, 38, 53).
Our results help bring into focus the dual evolutionary pressures
at work that separately select for resistance and fitness.
We were able to model the effect of reduced protease activity by
titrating down this activity using a phenotypic mixing strategy
with a protease active-site mutation, D25A (Fig. 6). The RC assay
was more sensitive to the loss of protease activity than the SpIn
assay (Fig. 6A). Consistent with the interpretation that loss in
protease activity results in increased sensitivity to protease inhib-
itors, the virus became increasingly sensitive to these inhibitors
with decreasing protease activity (Fig. 6B and C). However, when
we tested sensitivity to RT inhibitors, it became apparent that
reduced protease activity has pleiotropic effects due to its role in
processing the RT and integrase (IN) domains in the Gag-Pro-Pol
precursor. The reduced levels of Gag processing that are achieved
with reduced protease activity similarly affect the level of process-
ing of RT. Thus, as protease activity is lost, the RT domain is
underprocessed, resulting in reduced levels of RT (Fig. 6D). This
mechanism could also be at work to further reduce levels of pro-
tease; i.e., protease monomers are left in unprocessed or under-
processed Gag-Pro-Pol intermediates.
The effect of reduction of RT activity has previously been stud-
ied directly by phenotypic mixing with an RT active-site mutant,
and the results obtained (1) were similar to those seen here in the
context of reduced protease activity. Specifically, the EC50s for the
chain-terminating NRTIs are relatively insensitive to the levels of
RT activity (Fig. 6C and D). This is consistent with the idea that
while the probability of initiating or completing DNA synthesis is
sensitive to the concentration of RT, the probability of incorpo-
rating a chain-terminating nucleotide relative to a normal nucle-
otide is not a function of the RT concentration, which has also
been observed for the NRTI inhibitor 3TC (17, 51). The one ex-
ception is AZT, for which the EC50 changes with reduced pro-
tease/RT activity (Fig. 6C and D) and reduced RT activity (1). This
result has previously been seen in the context of protease inhibitor
resistance (13). This specific effect with AZT is likely due to the
fact that AZT remains in the nucleotide binding site in RT after
incorporation and does not translocate to the primer site, in con-
trast to the other NRTIs (4, 56). In the nucleotide binding site,
AZT is susceptible to an excision reaction using ATP which un-
caps the growing chain end and allows DNA synthesis to continue
(4, 36). The fact that this reaction shows a dependence on RT
concentration indicates that the RT molecule that incorporates
AZT is not always the same one that excises it; i.e., this can be a
distributive action that is dependent on the concentration of ac-
tive RT. Like the EC50 to AZT, the EC50 to NNRTIs is also sensitive
to reduced levels of protease/RT (Fig. 6C and D) and to reduced
levels of just RT (1, 25). Since the NNRTIs bind to a pocket in RT
to make it enzymatically inactive, the sensitivity of the EC50 to RT
concentration is strong evidence that viral DNA synthesis is dis-
tributive, involving multiple RT complexes whose availability in
the intracellular replication complex is concentration dependent.
The effect of total enzyme activity, either in the number/con-
centration of enzyme molecules or in the intrinsic activity of each
enzyme molecule, displays another feature with respect to inter-
action with inhibitors. Shen et al. (54) have reported that different
classes of inhibitors have different dose-response curves and that
at the higher levels of inhibition, protease inhibitors have the most
dramatic effect, with NNRTIs showing an intermediate effect and
NRTIs the least dramatic effect. This is attributed to the effect of
needing multiple enzyme molecules to complete either proteolytic
processing or DNA synthesis (55); the ordering of the inhibitors in
this analysis is the same as that seen when protease activity is
titrated down with an active-site mutant (Fig. 6B and C). Thus,
targeting the enzymes in pathways that require multiple enzyme
molecules to complete the process (virion assembly/maturation
and DNA synthesis) has the added benefit of a dynamic potency,
as increasing inhibition reduces the overall probability of comple-
tion of the process, thereby enhancing the sensitivity of the resid-
ual infectivity to further inhibition. Similarly, the loss of fitness
associated with protease inhibitor resistance mutations results in
fewer protease molecules (or less protease activity) being available
for processing in those virions where processing is successfully
completed, again sensitizing the assembly pathway to inhibition
by a protease inhibitor (50) (Fig. 6). The pleiotropic effects asso-
ciated with reduced activity of the viral protease likely account for
the persistent benefit that patients can experience even with viro-
logic failure to a protease inhibitor-based regimen (2, 11).
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